{
    "organizations": [],
    "uuid": "812eb4c48626309dfb2f099ef96c9d857b31cddb",
    "author": "",
    "url": "https://www.reuters.com/article/brief-merus-provides-clinical-updates-fo/brief-merus-provides-clinical-updates-for-mcla-117-and-mcla-158-programs-idUSASB0BZPX",
    "ord_in_thread": 0,
    "title": "BRIEF-Merus Provides Clinical Updates For Mcla-117 And Mcla-158 Programs",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 07 PM / Updated 9 minutes ago BRIEF-Merus Provides Clinical Updates For Mcla-117 And Mcla-158 Programs Reuters Staff \nJan 4 (Reuters) - Merus Nv: \n* MERUS PROVIDES CLINICAL UPDATES FOR MCLA-117 AND MCLA-158 PROGRAMS \n* MERUS NV - PLANS TO FILE AN IND FOR MCLA-158 WITH U.S. FDA IN Q1 OF 2018​ \n* MERUS NV - APPROVAL OF CLINICAL TRIAL APPLICATION IN BELGIUM, WHERE IT PLANS TO FIRST INITIATE PHASE 1, FIRST-IN-HUMAN CLINICAL TRIAL OF MCLA-158​ Source text for Eikon:  ",
    "published": "2018-01-04T14:06:00.000+02:00",
    "crawled": "2018-01-04T14:27:10.061+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "provides",
        "clinical",
        "update",
        "program",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "merus",
        "nv",
        "merus",
        "provides",
        "clinical",
        "update",
        "program",
        "merus",
        "nv",
        "plan",
        "file",
        "ind",
        "fda",
        "q1",
        "merus",
        "nv",
        "approval",
        "clinical",
        "trial",
        "application",
        "belgium",
        "plan",
        "first",
        "initiate",
        "phase",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon"
    ]
}